• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 HPMC 和纤维素酶的可蚀涂层用于口服药物的时间控制释放。

Erodible coatings based on HPMC and cellulase for oral time-controlled release of drugs.

机构信息

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

出版信息

Int J Pharm. 2020 Jul 30;585:119425. doi: 10.1016/j.ijpharm.2020.119425. Epub 2020 May 28.

DOI:10.1016/j.ijpharm.2020.119425
PMID:32473374
Abstract

Oral drug delivery systems for time-controlled release, intended for chronotherapy or colon targeting, are often in the form of coated dosage forms provided with swellable/soluble hydrophilic polymer coatings. These are responsible for programmable lag phases prior to release, due to their progressive hydration in the biological fluids. When based on high-viscosity polymers and/or manufactured by press-coating, the performance of functional hydroxypropyl methylcellulose (HPMC) layers was not fully satisfactory. Particularly, it encompassed an initial phase of slow release because of outward diffusion of the drug through a persistent gel barrier surrounding the core. To promote erosion of such a barrier, the use of a cellulolytic product (Sternzym® C13030) was here explored. For this purpose, the mass loss behavior of tableted matrices based on various HPMC grades, containing increasing percentages of Sternzym® C13030, was preliminarily studied, highlighting a clear and concentration-dependent effect of the enzyme especially with high-viscosity polymers. Subsequently, Sternzym® C13030-containing systems, wherein the cellulolytic product was either incorporated into a high-viscosity HPMC coating or formed a separate underlying layer, were manufactured. Evaluated for release, such systems gave rise to more reproducible profiles, with shortened lag phases and reduced diffusional release, as compared to the reference formulation devoid of enzyme.

摘要

用于时控释放的口服药物递送系统,旨在进行时间治疗或结肠靶向,通常采用具有可溶胀/水溶性亲水性聚合物涂层的包衣剂型。这些系统由于其在生物流体中的逐渐水合作用,负责可编程的滞后阶段,在释放之前。当基于高粘度聚合物和/或通过压制涂层制造时,功能性羟丙基甲基纤维素(HPMC)层的性能并不完全令人满意。特别是,由于药物通过围绕核心的持续凝胶屏障向外扩散,会出现初始缓慢释放阶段。为了促进这种屏障的侵蚀,本文探索了使用纤维素酶产品(Sternzym® C13030)。为此,初步研究了基于各种 HPMC 等级的片剂基质的质量损失行为,其中包含越来越多的 Sternzym® C13030,突出了酶的明显且浓度依赖性效应,特别是对于高粘度聚合物。随后,制造了含有 Sternzym® C13030 的系统,其中纤维素酶产品要么被掺入高粘度 HPMC 涂层中,要么形成单独的底层。与不含酶的参考配方相比,评估释放结果表明,这些系统产生了更可重复的曲线,滞后阶段缩短,扩散释放减少。

相似文献

1
Erodible coatings based on HPMC and cellulase for oral time-controlled release of drugs.基于 HPMC 和纤维素酶的可蚀涂层用于口服药物的时间控制释放。
Int J Pharm. 2020 Jul 30;585:119425. doi: 10.1016/j.ijpharm.2020.119425. Epub 2020 May 28.
2
Cellulase as an "active" excipient in prolonged-release HPMC matrices: A novel strategy towards zero-order release kinetics.纤维素酶作为一种“活性”赋形剂在 HPMC 缓释基质中的应用:一种实现零级释放动力学的新策略。
Int J Pharm. 2021 Sep 25;607:121005. doi: 10.1016/j.ijpharm.2021.121005. Epub 2021 Aug 13.
3
Erodible time-dependent colon delivery systems with improved efficiency in delaying the onset of drug release.具有提高延迟药物释放起始效率的可蚀性时间依赖性结肠给药系统。
J Pharm Sci. 2014 Nov;103(11):3585-3593. doi: 10.1002/jps.24150. Epub 2014 Sep 11.
4
Evaluation of powder-layering vs. spray-coating techniques in the manufacturing of a swellable/erodible pulsatile delivery system.粉末层积法与喷雾包衣法在可溶胀/蚀性脉冲释放给药系统制备中的评价。
Drug Dev Ind Pharm. 2020 Aug;46(8):1230-1237. doi: 10.1080/03639045.2020.1788060. Epub 2020 Jul 7.
5
Modified release from hydroxypropyl methylcellulose compression-coated tablets.羟丙甲纤维素包衣压片的控释。
Int J Pharm. 2010 Dec 15;402(1-2):72-7. doi: 10.1016/j.ijpharm.2010.09.021. Epub 2010 Sep 29.
6
Investigating effects of hydroxypropyl methylcellulose (HPMC) molecular weight grades on lag time of press-coated ethylcellulose tablets.研究羟丙基甲基纤维素(HPMC)分子量等级对压制包衣乙基纤维素片剂滞后时间的影响。
Pharm Dev Technol. 2016 Nov;21(7):794-802. doi: 10.3109/10837450.2015.1055767. Epub 2015 Jun 23.
7
Release Kinetics of Hydroxypropyl Methylcellulose Governing Drug Release and Hydrodynamic Changes of Matrix Tablet.羟丙基甲基纤维素的释放动力学及其对基质片剂药物释放和流体动力学变化的影响。
Curr Drug Deliv. 2022;19(5):520-533. doi: 10.2174/1567201818666210820101549.
8
Formulation, development, and evaluation of floating pulsatile drug delivery system of atenolol.阿替洛尔胃内漂浮脉冲式给药系统的制剂、开发与评价
PDA J Pharm Sci Technol. 2013 May-Jun;67(3):214-28. doi: 10.5731/pdajpst.2013.00916.
9
Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds.口服双脉冲结肠释放蛋白药物和蛋白酶抑制剂/吸收增强剂化合物的递送系统。
J Pharm Sci. 2011 Aug;100(8):3251-3259. doi: 10.1002/jps.22560. Epub 2011 Apr 4.
10
The influence of polymer content on early gel-layer formation in HPMC matrices: The use of CLSM visualisation to identify the percolation threshold.聚合物含量对羟丙基甲基纤维素基质中早期凝胶层形成的影响:使用共聚焦激光扫描显微镜可视化来确定渗流阈值。
Eur J Pharm Biopharm. 2015 Aug;94:485-92. doi: 10.1016/j.ejpb.2015.06.019. Epub 2015 Jul 2.

引用本文的文献

1
Colon Drug Delivery Systems Based on Swellable and Microbially Degradable High-Methoxyl Pectin: Coating Process and In Vitro Performance.基于可溶胀和微生物可降解高甲氧基果胶的结肠给药系统:包衣工艺及体外性能
Pharmaceutics. 2024 Apr 7;16(4):508. doi: 10.3390/pharmaceutics16040508.
2
Time-Based Formulation Strategies for Colon Drug Delivery.结肠给药的基于时间的制剂策略
Pharmaceutics. 2022 Dec 9;14(12):2762. doi: 10.3390/pharmaceutics14122762.
3
The Chronotopic™ System for Pulsatile and Colonic Delivery of Active Molecules in the Era of Precision Medicine: Feasibility by 3D Printing via Fused Deposition Modeling (FDM).
精准医学时代用于活性分子脉冲式和结肠递送的Chronotopic™系统:通过熔融沉积建模(FDM)3D打印实现的可行性
Pharmaceutics. 2021 May 20;13(5):759. doi: 10.3390/pharmaceutics13050759.